Designing phase II clinical trials in Friedreich ataxia

References

• Durr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med. 1996;335(16):1169–1175.
   PubMed Web of Science ®Google Scholar
• Bidichandani SI, Ashizawa T, Patel PI. Atypical Friedreich ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triplet-repeat expansion. Am J Hum Genet. 1997;60(5):1251–1256.
   PubMed Web of Science ®Google Scholar
• Cossee M, Durr A, Schmitt M, et al. Friedreich’s ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol. 1999;45(2):200–206.
   PubMed Web of Science ®Google Scholar
• Zuhlke CH, Dalski A, Habeck M, et al. Extension of the mutation spectrum in Friedreich’s ataxia: detection of an exon deletion and novel missense mutations. Eur J Hum Genet. 2004;12(11):979–982.
   PubMed Web of Science ®Google Scholar
• Campuzano V, Montermini L, Molto MD, et al. Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271(5254):1423–1427.
   PubMed Web of Science ®Google Scholar
• Bidichandani SI, Ashizawa T, Patel PI. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet. 1998 Jan;62(1):111–121.
   PubMed Web of Science ®Google Scholar
• Punga T, Buhler M. Long intronic GAA repeats causing Friedreich ataxia impede transcription elongation. EMBO Mol Med. 2010 Apr;2(4):120–129.
   PubMed Web of Science ®Google Scholar
• Groh M, Lufino MM, Wade-Martins R, et al. R-loops associated with triplet repeat expansions promote gene silencing in Friedreich ataxia and fragile X syndrome. PLoS Genet. 2014;10(5):e1004318.
   PubMed Web of Science ®Google Scholar
• Chutake YK, Costello WN, Lam C, et al. Altered nucleosome positioning at the transcription start site and deficient transcriptional initiation in Friedreich ataxia. J Biol Chem. 2014;289(22):15194–15202.
   PubMed Web of Science ®Google Scholar
• Rodden LN, Chutake YK, Gilliam K, et al. Methylated and unmethylated epialleles support variegated epigenetic silencing in Friedreich ataxia. Hum Mol Genet. 2021;29(23):3818–3829.
   PubMed Web of Science ®Google Scholar
• Geoffroy G, Barbeau A, Breton G, et al. Clinical description and roentgenologic evaluation of patients with Friedreich’s ataxia. Can J Neurol Sci. 1976;3(4):279–286.
   PubMedGoogle Scholar
• Koeppen AH, Becker AB, Qian J, et al. Friedreich ataxia: hypoplasia of spinal cord and dorsal root ganglia. J Neuropathol Exp Neurol. 2017;76(2):101–108.
   PubMed Web of Science ®Google Scholar
• Koeppen AH, Becker AB, Qian J, et al. Friedreich ataxia: developmental failure of the dorsal root entry zone. J Neuropathol Exp Neurol. 2017;76(11):969–977.
   PubMed Web of Science ®Google Scholar
• Koeppen AH, Mazurkiewicz JE. Friedreich ataxia: neuropathology revised. J Neuropathol Exp Neurol. 2013 Feb;72(2):78–90.
   PubMed Web of Science ®Google Scholar
• Solbach K, Kraff O, Minnerop M, et al. Cerebellar pathology in Friedreich’s ataxia: atrophied dentate nuclei with normal iron content. Neuroimage Clin. 2014;6:93–99.
   PubMed Web of Science ®Google Scholar
• Ackroyd RS, Finnegan JA, Green SH. Friedreich’s ataxia. A clinical review with neurophysiological and echocardiographic findings. Arch Dis Child. 1984 Mar;59(3):217–221.
   PubMed Web of Science ®Google Scholar
• Filla A, De Michele G, Cavalcanti F, et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet. 1996 Sep;59(3):554–560.
   PubMed Web of Science ®Google Scholar
• Delatycki MB, Paris DB, Gardner RJ, et al. Clinical and genetic study of Friedreich ataxia in an Australian population. Am J Med Genet. 1999;87(2):168–174.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Schadt K, Kichula E, et al. Friedreich ataxia: multidisciplinary clinical care. J Multidiscip Healthc. 2021;14:1645–1658.
   PubMed Web of Science ®Google Scholar
• Strawser C, Schadt K, Hauser L, et al. Pharmacological therapeutics in Friedreich ataxia: the present state. Expert Rev Neurother. 2017;17(9):895–907.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Willi SM, Wilson RB, et al. A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial. Mov Disord. 2012;27(8):1026–1033.
   PubMed Web of Science ®Google Scholar
• Zesiewicz T, Salemi JL, Perlman S, et al. Double-blind, randomized and controlled trial of EPI-743 in Friedreich’s ataxia. Neurodegener Dis Manag. 2018;8(4):233–242.
   PubMed Web of Science ®Google Scholar
• Regner SR, Wilcox NS, Friedman LS, et al. Friedreich ataxia clinical outcome measures: natural history evaluation in 410 participants. J Child Neurol. 2012;27(9):1152–1158.
   PubMed Web of Science ®Google Scholar
• Tomassini B, Arcuri G, Fortuni S, et al. Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model. Hum Mol Genet. 2012;21(13):2855–2861.
   PubMed Web of Science ®Google Scholar
• Marcotulli C, Fortuni S, Arcuri G, et al. GIFT-1, a phase IIa clinical trial to test the safety and efficacy of IFNgamma administration in FRDA patients. Neurol Sci. 2016;37(3):361–364.
   PubMed Web of Science ®Google Scholar
• Seyer L, Greeley N, Foerster D, et al. Open-label pilot study of interferon gamma-1b in Friedreich ataxia. Acta Neurol Scand. 2015;132(1):7–15.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Hauser L, McCormick A, et al. Randomized, double-blind, placebo-controlled study of interferon-gamma 1b in Friedreich ataxia. Ann Clin Transl Neurol. 2019;6(3):546–553.
   PubMed Web of Science ®Google Scholar
• Wells M, Seyer L, Schadt K, et al. IFN-gamma for Friedreich ataxia: present evidence. Neurodegener Dis Manag. 2015;5(6):497–504.
   PubMed Web of Science ®Google Scholar
• Zesiewicz T, Heerinckx F, De Jager R, et al. Randomized, clinical trial of RT001: early signals of efficacy in Friedreich’s ataxia. Mov Disord. 2018;33(6):1000–1005.
   PubMed Web of Science ®Google Scholar
• Reisman SA, Lee CY, Meyer CJ, et al. Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin. Arch Dermatol Res. 2014;306(5):447–454.
   PubMed Web of Science ®Google Scholar
• Abeti R, Uzun E, Renganathan I, et al. Targeting lipid peroxidation and mitochondrial imbalance in Friedreich’s ataxia. Pharmacol Res. 2015;99:344–350.
   PubMed Web of Science ®Google Scholar
• Hayashi G, Cortopassi G, Fang D. Lymphoblast oxidative stress genes as potential biomarkers of disease severity and drug effect in Friedreich’s ataxia. PLoS One. 2016;11(4):e0153574.
   PubMed Web of Science ®Google Scholar
• Petrillo S, D’Amico J, La Rosa P, et al. Targeting NRF2 for the treatment of Friedreich’s ataxia: a comparison among drugs. Int J Mol Sci. 2019;20(20):5211. PMID: 31640150; PMCID: PMC6829337.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Farmer J, Hauser L, et al. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Ann Clin Transl Neurol. 2019;6(1):15–26.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Chin MP, Delatycki MB, et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study). Ann Neurol. 2021;89(2):212–225.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Johnson J. Omaveloxolone: potential new agent for Friedreich ataxia. Neurodegener Dis Manag. 2021 Apr;11(2):91–98.
   PubMed Web of Science ®Google Scholar
• Guo L, Wang Q, Weng L, et al. Liquid chromatography-high resolution mass spectrometry analysis of platelet frataxin as a protein biomarker for the rare disease Friedreich’s ataxia. Anal Chem. 2018;90(3):2216–2223.
   PubMed Web of Science ®Google Scholar
• Guo L, Wang Q, Weng L, et al. Characterization of a new N-terminally acetylated extra-mitochondrial isoform of frataxin in human erythrocytes. Sci Rep. 2018;8(1):17043.
   PubMedGoogle Scholar
• Deutsch EC, Oglesbee D, Greeley NR, et al. Usefulness of frataxin immunoassays for the diagnosis of Friedreich ataxia. J Neurol Neurosurg Psychiatry. 2014;85(9):994–1002.
   PubMed Web of Science ®Google Scholar
• Lazaropoulos M, Dong Y, Clark E, et al. Frataxin levels in peripheral tissue in Friedreich ataxia. Ann Clin Transl Neurol. 2015;2(8):831–842.
   PubMed Web of Science ®Google Scholar
• Worth AJ, Basu SS, Deutsch EC, et al. Stable isotopes and LC-MS for monitoring metabolic disturbances in Friedreich’s ataxia platelets. Bioanalysis. 2015;7(15):1843–1855.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Farmer G. Mitochondrial and metabolic dysfunction in Friedreich ataxia: update on pathophysiological relevance and clinical interventions. Neuronal Sign. 2021;5(2):NS20200093.
   PubMedGoogle Scholar
• Rummey C, Zesiewicz TA, Perez-Lloret S, et al. Test-retest reliability of the Friedreich’s ataxia rating scale. Ann Clin Transl Neurol. 2020;7(9):1708–1712.
   PubMed Web of Science ®Google Scholar
• Hamedani AG, Hauser LA, Perlman S, et al. Longitudinal analysis of contrast acuity in Friedreich ataxia. Neurol Genet. 2018;4(4):e250.
   PubMed Web of Science ®Google Scholar
• Reetz K, Dogan I, Hilgers RD, et al. Progression characteristics of the European Friedreich’s ataxia consortium for translational studies (EFACTS): a 2 year cohort study. Lancet Neurol. 2016;15(13):1346–1354.
   PubMed Web of Science ®Google Scholar
• Reetz K, Dogan I, Hilgers RD, et al. Progression characteristics of the European Friedreich’s ataxia consortium for translational studies (EFACTS): a 4-year cohort study. Lancet Neurol. 2021;20(5):362–372.
   PubMed Web of Science ®Google Scholar
• Patel M, Isaacs CJ, Seyer L, et al. Progression of Friedreich ataxia: quantitative characterization over 5 years. Ann Clin Transl Neurol. 2016;3(9):684–694.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Mastronardi A, Scarafino A, et al. Motor-evoked potentials in amyotrophic lateral sclerosis: potential implications in detecting subclinical UMN involvement in lower motor neuron phenotype. J Neurol. 2020;267(12):3689–3695.
   PubMed Web of Science ®Google Scholar
• Seyer LA, Galetta K, Wilson J, et al. Analysis of the visual system in Friedreich ataxia. J Neurol. 2013;260(9):2362–2369.
   PubMed Web of Science ®Google Scholar
• Noval S, Contreras I, Sanz-Gallego I, et al. Ophthalmic features of Friedreich ataxia. Eye (Lond). 2012;26(2):315–320.
   PubMed Web of Science ®Google Scholar
• Rojas P, Ramirez AI, Hoz R, et al. Ocular involvement in Friedreich ataxia patients and its relationship with neurological disability, a follow-up study. Diagnostics (Basel). 2020;10(2):75.
   Google Scholar
• Dag E, Ornek N, Ornek K, et al. Optical coherence tomography and visual field findings in patients with Friedreich ataxia. J Neuroophthalmol. 2014;34(2):118–121.
   PubMed Web of Science ®Google Scholar
• Fortuna F, Barboni P, Liguori R, et al. Visual system involvement in patients with Friedreich’s ataxia. Brain. 2009;132(Pt 1):116–123.
   PubMed Web of Science ®Google Scholar
• Parkinson MH, Bartmann AP, Clayton LMS, et al. Optical coherence tomography in autosomal recessive spastic ataxia of Charlevoix-Saguenay. Brain. 2018;141(4):989–999.
   PubMed Web of Science ®Google Scholar
• Piemonte F, Pastore A, Tozzi G, et al. Glutathione in blood of patients with Friedreich’s ataxia. Eur J Clin Invest. 2001;31(11):1007–1011.
   PubMed Web of Science ®Google Scholar